Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Next Previous
Trial Profile

Chemoradiation With Gemcitabine in Combination With Panitumumab for Patients With Locally Advanced Pancreatic Cancer

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panitumumab (Primary) ; Gemcitabine
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

Most Recent Events

  • 17 Mar 2017 Status changed from active, no longer recruiting to completed.
  • 02 Jun 2015 Planned primary completion date changed from 1 Apr 2014 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
  • 13 Jun 2013 Planned end date changed from 1 Apr 2013 to 1 Apr 2014 as reported by ClinicalTrials.gov record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top